AI News for Nov 01, 2024
Welcome to 'The Automated Daily', your ultimate source for a streamlined and insightful daily news experience. Please support this podcast by checking out our sponsors: -Get $1,000 off the purchase of a Tesla product - https://ts.la/ron46932 -Stock MVP: 25% off for life - https://www.stock-mvp.com -Boost your business with Ramp! Save time and money with smarter expense management. $250 credit - https://ramp.com/?rc=8BZ8BZ Today's topics: -Bytedance's Bytespider AI crawler -ChatGPT anniversary reflections -Open Source AI Definition controversy -Google's Gemini API grounding -AI Homeworkify homework assistance -Humane Inc. Charge Case recall -Anthropic's Claude app criticism -Eric Schmidt on AI drones - https://www.haproxy.com/blog/nearly-90-of-our-ai-crawler-traffic-is-from-tiktok-parent-bytedance-lessons-learned - https://halcyon.eco/blog/building-with-ai - https://sfconservancy.org/blog/2024/oct/31/open-source-ai-definition-osaid-erodes-foss/ - https://developers.googleblog.com/en/gem
Today's AI News Topics
- 01
Bytedance's Bytespider AI crawler
— Bytedance's Bytespider AI crawler - 02
ChatGPT anniversary reflections
— ChatGPT anniversary reflections - 03
Open Source AI Definition controversy
— Open Source AI Definition controversy - 04
Google's Gemini API grounding
— Google's Gemini API grounding - 05
AI Homeworkify homework assistance
— AI Homeworkify homework assistance - 06
Humane Inc. Charge Case recall
— Humane Inc. Charge Case recall - 07
Anthropic's Claude app criticism
— Anthropic's Claude app criticism - 08
Eric Schmidt on AI drones
— Eric Schmidt on AI drones
Sources & AI News References
More from AI News
- August 20, 2026 OpenAI slows frontier scaling & Open-weight models get practical
- August 19, 2026 Zero-click risks in AI browsers & Benchmarks for discovery and trust
- August 18, 2026 Chatbots face influence operations & Open models push the frontier
- August 17, 2026 AI Manager Forgets Its Rules & Stripe Buys OpenRouter
- August 16, 2026 AI memory versus real reasoning & Drug discovery hype meets evidence